【著作權嚴正聲明】

本線上課程內容受著作權法保護，本學苑僅授權報名並完成繳費之個人學員自我學習，同一帳號僅授權一人使用，

如超越前述範圍之使用，其他第三人或企業應另先依規定取得授權，不得自行側錄或以其他方式重製、公開播放、公開傳輸、散布，

情節嚴重者，處三年以下有期徒刑、拘役，或科或併科新臺幣七十五萬元以下罰金，敬請務必謹慎使用，以免觸法。

【購課者需知】

為維護購課者對於專業生技醫藥課程的重視程度與學習效率，故本課程在購買後具有10天的觀看時限。

溫馨提醒：購買此課程前請思考自身是否能在期限內完成學習，逾期者如欲繼續學習，煩請來信bioschool@biotech-edu.com洽詢。

【電子證書領取步驟】

【企業團體優惠】

企業團體多人觀看另有優惠價格，請洽 02-2545-9721。

【課程內容】

FDA臨床開發情境設定說明：以糖尿病新藥為例

TPP與CDP如何讓臨床研發事半功倍？

TPP與CDP的臨床和商業意義：提問與討論

製作TPP的思維架構

TPP案例分享：提問與討論
(FDA Case Study: Drug Approval – Bringing a New Drug to The Market)

製作CDP的思維架構

CDP案例分享：提問與討論 
(FDA Case Study: Drug Approval – Bringing a New Drug to The Market)

如何將TPP與CDP的思維帶入組織的研發決策？

TPP與CDP的實務運用：提問與討論

Q & A

【師資介紹】

陳昱宏 Bert Chen CMPP Cochrane Member

現職：

Vercentrys Biomedical Director Vercentrys Taiwan
Advisory Board, Drug Research Center, NTU
Industry Consultant, Center for Biotechnology, NTU
Translation Consultant, National Palace Museum
Professional Experience:

2021:

— TPP and CDP for new modality drug
— TPP and CDP for novel cell therapy
— TPP for novel anticancer small molecule drug
— TPP for novel antidiabetic small molecule drug

2020:

— TPP and CDP for novel anticancer monoclonal antibody
— TPP and CDP for novel antirheumatic monoclonal antibody
— TPP for novel anticancer small molecule drug

2019:

— TPP and CDP for rheumatoid arthritis biosimilar
— TPP for novel lung cancer imaging technique

Certification:

Certified Medical Publication Professional, International Society for Medical Publication Professionals (ISMPP)
Accredited Chinese-English Translator, Ministry of Education
N1 Japanese Language Proficiency Certificate

Awards:

2020 Gold Award for Patient Education Booklet, Health Promotion Administration of the Ministry of Health and Welfare
2019 Silver Award for Patient Education Booklet, Health Promotion Administration of the Ministry of Health and Welfare